Wu Guo-Yi, Chen Hong-Song
Hepatology Institute, People's Hospital, Peking University, Beijing 100044, China.
World J Gastroenterol. 2007 Feb 14;13(6):830-6. doi: 10.3748/wjg.v13.i6.830.
Currently approved treatments for hepatitis B virus (HBV) infection include the immunomodulatory agent, IFN-alpha, and nucleos(t)ide analogues. Their efficacy is limited by their side effects, as well as the induction of viral mutations that render them less potent. It is thus necessary to develop drugs that target additional viral antigens. Chemicals and biomaterials by unique methods of preventing HBV replication are currently being developed, including novel nucleosides and newly synthesized compounds such as capsid assembling and mRNA transcription inhibitors. Molecular therapies that target different stages of the HBV life cycle will aid current methods to manage chronic hepatitis B (CHB) infection. The use of immunomodulators and gene therapy are also under consideration. This report summarizes the most recent treatment possibilities for CHB infection. Emerging therapies and their potential mechanisms, efficacy, and pitfalls are discussed.
目前批准用于治疗乙型肝炎病毒（HBV）感染的药物包括免疫调节剂α干扰素以及核苷（酸）类似物。它们的疗效受到副作用以及诱导病毒突变从而使其效力降低的限制。因此，有必要研发针对其他病毒抗原的药物。目前正在通过独特的方法开发用于预防HBV复制的化学物质和生物材料，包括新型核苷以及新合成的化合物，如衣壳组装和mRNA转录抑制剂。针对HBV生命周期不同阶段的分子疗法将有助于当前管理慢性乙型肝炎（CHB）感染的方法。免疫调节剂和基因疗法的应用也在考虑之中。本报告总结了CHB感染最新的治疗可能性。讨论了新兴疗法及其潜在机制、疗效和缺陷。
